Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin’s UK Subsidiary Acquires Global Commercial Rights to Cancer Pain Drug Except Japan and US
June 6, 2012
- Tivantinib Significantly Improves TTP in HCC Patients: Daiichi Sankyo
June 6, 2012
- Takeda Completes Acquisition of URL Pharma; to Enhance Gout Field
June 6, 2012
- Eisai Boosts Alliance with Subsidiaries to Develop Diagnostic Agents
June 5, 2012
- Volume Discounts Are Naturally Expected in Price Negotiations: President Otani of Ain Pharmaciez
June 5, 2012
- MTPC to Terminate Development of Novel Vitamin D Compound Lunacalcipol in US
June 5, 2012
- RaQualia Begins PI Study for 5-HT4 Partial Agonist in UK
June 5, 2012
- Eisai Files for Triple Formulation Packs Including Pariet for H. Pylori Eradication
June 4, 2012
- SymBio to Postpone Filing for Supplemental NDA of Treakisym for Indication of Aggressive NHL
June 4, 2012
- Janssen Research & Development Files NDA for MTPC’s SGLT-2 Canagliflozin in the US
June 4, 2012
- Sawai Ranked Forerunner Among Drug Makers to Sell 3 Major Generics: Pharmacist Survey
June 1, 2012
- Ono Pharmaceutical to Collaborate with UK Company in Research of Drug Targets for Allergic Diseases
June 1, 2012
- Taiho to Initiate Global PIII Trial for Anticancer Agent TAS-102 in June
June 1, 2012
- MicroBiopharm Japan Announces Joint R&D Agreement with Eisai in Search of Compounds Derived from Natural Substances
June 1, 2012
- “Some Aspects Might Have Been Overlooked” in Actavis Adaptation Scenario: ASKA President Yamaguchi
May 31, 2012
- CJ CheilJedang of Korea to hold R&D Forum with 6 Ventures in Japan
May 31, 2012
- Kyowa Kirin Launches Its First Antibody Drug Poteligeo for ATL
May 31, 2012
- Pfizer Launches ALK Inhibitor Xalkori, Administered to 51 Patients Prior to NHI Price Listing
May 30, 2012
- Kyorin Holdings to Boost Manufacturing System with Transfer of MSD Plant
May 30, 2012
- Shionogi Launches Oxycodone Injections in Response to Request for Development
May 30, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…